General

Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Fortify Henan for Flood Relief and Preventing Epidemic



HONG KONG, July 22, 2021 – (ACN Newswire) – Sino Biopharmaceutical Exiguous (“Sino Biopharmaceutical” or the “Company”, alongside with its subsidiaries, the “Community”) (HKEX: 1177), a leading and innovation-driven pharmaceutical conglomerate within the PRC, has launched the donation of money and gives valued at RMB10 million to toughen Henan for flood reduction and stopping epidemic.

Henan province has been afflicted by the torrential rain storm and the severe flooding has drawn frequent area. When a collection up is in distress, help from all facets come to the rescue. With this thought in mind, Sino Biopharmaceutical, in gratifying its social responsibility and living as much as its role as a pharmaceutical firm dedicated to healthcare, has donated both cash and emergency reduction gives every valued at RMB5 million via the Liaison Set up of job of the Central Folks’s Authorities within the Hong Kong S.A.R. These funds and gives are to be passe in supporting Henan province’s efforts to salvage emergency scientific and rescue and reduction products and services and pause the emergence of an endemic of illness or a virus within the wake of the devastation so that you just can offer protection to the lives, security and health of the general public in Henan.

Ms. Cheng Cheung Ling, Vice Chairwoman and Government Director of Sino Biopharmaceutical, mentioned, “Capitalising on its educated strengths within the biopharmaceutical alternate, the Community will closely be conscious health factors and epidemic prevention preparations subsequent to this natural catastrophe, and donate gives and medicines. Sino Biopharmaceutical regards safeguarding public health as its mission and responsibility. Let’s cease together through thick and skinny. Have battling and develop now not quit, Henan!”

About Sino Biopharmaceutical Exiguous (HKEX: 1177)

Sino Biopharmaceutical Exiguous is a leading, innovative R&D driven pharmaceutical conglomerate within the PRC. Its alternate incorporates a entirely-integrated chain which covers an array of R&D platforms, a line-up of vivid manufacturing and a stable gross sales system. The Community’s products bask in gained a competitive foothold in varied therapeutic classes with promising potentials, comprising a vary of biopharmaceutical and chemical medicines for tumors, liver illnesses, cardio-cerebral illnesses, orthopedic illnesses, respiratory system illnesses and parenteral food plan.

Sino Biopharm is a constituent stock of the next indices: MSCI World Long-established Indices – MSCI China Index, Cling Seng Index, Cling Seng China Enterprises Index, Cling Seng Composite Index, Cling Seng Healthcare Index, Cling Seng SCHK Mainland China Healthcare Index, Cling Seng Composite LargeCap Index, Cling Seng Composite LargeCap & MidCap Index, Cling Seng China (Hong Kong-listed) 100 Index and Cling Seng Stock Join Hong Kong Index, and plenty of others.. Sino Biopharm was once ranked as one amongst “Asia’s Fab 50 Firms” by Forbes Asia for 3 consecutive years in 2016, 2017 and 2018.

For more records:

Strategic Financial Kin Exiguous

Vicky Lee +852 2864 4834 [email protected]

Fanny Yuen +852 2864 4853 [email protected]

Mandy Wong +852 2114 4900 [email protected]

Net deliver: www.sprg.com.hk


Matter: Press liberate summary



Supply: Sino Biopharmaceutical Exiguous


Sectors: BioTech


http://www.acnnewswire.com


From the Asia Company Knowledge Community

Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Company Knowledge Community.


Related Articles

Back to top button
%d bloggers like this: